about
Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.[New disease markers within the chronic myeloproliferative neoplasms].[Status and perspectives on chronic myeloproliferative neoplasm treatment].Cancer immune therapy for myeloid malignancies: present and futureGenetic variants in theP2RX7gene are associated with risk of multiple myelomaHigh frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytesSpontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical responseThe CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasmsJAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation[Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia]Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutationNeo-antigen specific memory T-cell responses in healthy individualsEvidence of immune elimination, immuno-editing and immune escape in patients with hematological cancerProgression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy
P50
Q33422507-946D83E6-15A4-4EC3-A0AA-26238A4DD1F5Q36169641-FEC392C5-637D-499D-9CCE-B8F0C3C79E67Q48178961-A75E2DDD-47F0-4517-8AEF-0BC43BC56917Q48289524-06CBDA51-0EF4-4C6D-BA42-930CAF076354Q50545414-616AA637-E58D-4E24-825B-8F2A426E60B6Q53509921-E6ABC139-F503-4DA3-8721-CDEE7F0E4868Q55059302-84641AF2-859D-4BDF-8CA8-924AA3D07B5BQ57176814-F2351482-939E-4196-A9C1-3BC0764DBF1EQ59245046-9CB70BA4-485E-4510-A088-6486310A3A42Q60820768-EF0017C2-D3E5-4993-A6AF-D07F7D23F3C0Q61698758-1B5B8497-92E1-4BE6-9F88-D2CE34D8E8A9Q61698761-86D1E308-3B85-42C7-9FE7-987743C1707AQ61698772-77B6CFEE-16A3-42B9-A4E3-99B63AB9604DQ63728935-9DC711C7-8703-4CB3-9506-A73A584AA5CDQ85069569-ECCA1437-6FF4-48BE-A84D-684840DEC701Q91523738-681D0451-43D3-4A9D-B82B-955BB32EBCCCQ92385638-E8D31646-F00B-4200-9012-73C56A00E15CQ92506646-387C8144-DD8D-41EE-BE55-9569627F7E39Q93135596-A1739262-F705-447F-AD5C-55C274BA7020
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Morten Orebo Holmström
@en
Morten Orebo Holmström
@nl
type
label
Morten Orebo Holmström
@en
Morten Orebo Holmström
@nl
prefLabel
Morten Orebo Holmström
@en
Morten Orebo Holmström
@nl
P31
P496
0000-0002-3764-8578